BR Biopharma (NASDAQ:BRBI – Get Free Report) is one of 1,748 public companies in the “Capital Markets” industry, but how does it weigh in compared to its rivals? We will compare BR Biopharma to related businesses based on the strength of its dividends, earnings, institutional ownership, valuation, profitability, analyst recommendations and risk.
Institutional & Insider Ownership
30.5% of shares of all “Capital Markets” companies are owned by institutional investors. 29.4% of BR Biopharma shares are owned by company insiders. Comparatively, 13.0% of shares of all “Capital Markets” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Dividends
BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.7%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.1% and pay out 30.8% of their earnings in the form of a dividend.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| BR Biopharma | N/A | N/A | N/A |
| BR Biopharma Competitors | 267.08% | 78.00% | 3.52% |
Analyst Ratings
This is a summary of recent recommendations for BR Biopharma and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BR Biopharma | 1 | 0 | 0 | 0 | 1.00 |
| BR Biopharma Competitors | 5369 | 19703 | 21888 | 613 | 2.37 |
As a group, “Capital Markets” companies have a potential upside of 25.97%. Given BR Biopharma’s rivals stronger consensus rating and higher probable upside, analysts clearly believe BR Biopharma has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares BR Biopharma and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BR Biopharma | $2.23 billion | $31.36 million | 140.26 |
| BR Biopharma Competitors | $2.48 billion | $396.83 million | 9.27 |
BR Biopharma’s rivals have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Summary
BR Biopharma rivals beat BR Biopharma on 11 of the 14 factors compared.
BR Biopharma Company Profile
BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.
Receive News & Ratings for BR Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BR Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
